

61. (New) The isolated polynucleotide of claim 60 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.

62. (New) The isolated nucleic acid molecule of claim 41, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

63. (New) The isolated nucleic acid molecule of claim 41, wherein the nucleotide sequence encodes a polypeptide comprising at least one amino acid substitution corresponding to amino acids 316 to 332 of SEQ ID NO:6.

REMARKS

In the Specification:

The specification was amended to append an omitted Figure legend for Figure 7 to the previously submitted Substitute Specification, submitted June 19, 2001. Support for this amendment may be found in the specification as originally submitted, in addition to the previously submitted Substitute Specification. Specifically, support for the appended legend for Figure 7 may be found in Figure 7, on page 26 of the Specification as originally submitted, and on page 25 of the Substitute Specification. No new matter has been added. A marked copy of this paragraph delineating each amendment is submitted herewith.

In the Claims:

Claims 1 to 40 have been cancelled and new claims 41 to 63 have been added. Support for the newly added claims may be found in the application, and claims, as originally filed. Specifically, support for new claims 41 to 54, and claims 62 to 63 may be found in originally filed claims 1-5, 7, 8, 11, 14-26, 29, 33, and 38, on pages 11, 52, 55 to 64, 143, 146, Figures 3A-C, Examples 8, 15, 16, and 17, and throughout the application as originally filed. Support for new claims 55 to 57, and claims 59 to 61 may be found on pages 103 and 104 of the application as originally filed. Support for new claim 58 may be found on pages 5, 11, and 71 of the application as originally filed. No new matter has been added. Applicants believe that all of the pending claims before the Examiner are in condition for allowance. An early Office Action to that effect is, therefore, earnestly solicited.

CONCLUSION


Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made**".

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.


If the Examiner wishes to discuss any aspect of this case, he is invited to contact the undersigned agent at the telephone number below.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: October 25, 2002



CASE D0016 NP

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Please amend the substitute specification, submitted June 19, 2001, as follows:

On page 13, please append the following paragraph on line 5 as the first paragraph on page 13:

Figure 7 shows a Kyte-Doolittle hydropathy plot of the novel Drosophila tumor necrosis factor class gene, DmTNF, of the present invention. As shown, the hydropathy plot suggests that DmTNF is a type II transmembrane protein (e.g., potentially secreted protein), with a short intracellular domain at the NH2 terminal of DmTNF and a long extracellular domain at the COOH terminal of DmTNF.

RECEIVED

OCT 31 2002

TECH CENTER 1600/2900